APASL consensus statements and management algorithms for hepatitis C virus infection. - Wikidata - wikimedia - TriplyDB

APASL consensus statements and management algorithms for hepatitis C virus infection.

APASL consensus statements and management algorithms for hepatitis C virus infection.

http://www.wikidata.org/entity/Q38552131

about

Hepatitis C genotype 6: A concise review and response-guided therapy proposal Hepatitis C virus protease inhibitor-resistance mutations: our experience and review Conceptual framework for outcomes research studies of hepatitis C: an analytical review Noninvasive Diagnosis of Hepatocellular Carcinoma: Elaboration on Korean Liver Cancer Study Group-National Cancer Center Korea Practice Guidelines Compared with Other Guidelines and Remaining Issues Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma Factors associated with the response to interferon-based antiviral therapies for chronic hepatitis C New treatments for genotype 1 chronic hepatitis C - focus on simeprevir A 2015 roadmap for the management of hepatitis C virus infections in Asia Hepatitis C virus infection among injection drug users with and without human immunodeficiency virus co-infection Changing Epidemiology of Hepatitis C Virus Genotype among Patients with Human Immunodeficiency Virus/Hepatitis C Virus Co-Infection in China Personalized Therapy of Chronic Hepatitis C and B Dually Infected Patients With Pegylated Interferon Plus Ribavirin: A Randomized Study APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing.Consensus Statement of HCV Task Force of the Indian National Association for Study of the Liver (INASL). Part II: INASL Recommendations for Management of HCV in India.Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data Platelet count and sustained virological response in hepatitis C treatment.Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa.Impact of host IL28B rs12979860, rs8099917 in interferon responsiveness and advanced liver disease in chronic genotype 3 hepatitis C patients.Peginterferon alfa-2a is associated with elevations in alanine aminotransferase at the end of treatment in chronic hepatitis C patients with sustained virologic response Disease Burden, Early Discontinuation, and Healthcare Costs in Hepatitis C Patients with and without Chronic Kidney Disease Treated with Interferon-Free Direct-Acting Antiviral Regimens.Pegylated interferon alfa-2b plus ribavirin for treatment of chronic hepatitis C.Modulation of TLR 3, 7 and 8 expressions in HCV genotype 3 infected individuals: potential correlations of pathogenesis and spontaneous clearance.Hepatitis C virus NS5A inhibitors and drug resistance mutations.Virological predictors of response to retreatment in hepatitis C genotype 2 infected patients.Efficacy and Tolerability of Peginterferon α -2a and Peginterferon α -2b, Both plus Ribavirin, for Chronic Hepatitis C: A Meta-Analysis of Randomized Controlled Trials Hepatitis C and kidney disease: An overview and approach to management.Viral hepatitis and human immunodeficiency virus co-infections in Asia Comparison Stratagems of Post-Screening Management of Anti-HCV-Positive Community Residents: Simple Notification, Active Referral, or Accessible Medical Care.Characterization of the Interleukin-28B Gene rs12979860 C/T Polymorphism in Turkish Chronic Hepatitis C Patients and Healthy Individuals.Retreatment of Chronic Hepatitis C Infection with Telaprevir: Preliminary Results in Turkey.Hepatitis C virus genotype and subtype distribution in Chinese chronic hepatitis C patients: nationwide spread of HCV genotypes 3 and 6.Current management of patients with hepatocellular carcinoma.Direct-acting Antiviral Agents for the Treatment of Chronic Hepatitis C Virus Infection.Is the use of IL28B genotype justified in the era of interferon-free treatments for hepatitis C?Huge gap between clinical efficacy and community effectiveness in the treatment of chronic hepatitis C: a nationwide survey in Taiwan.Successful sofosbuvir treatment with ribavirin dose reduction for chronic hepatitis C virus genotype 2 infection in a patient with ulcerative colitis: a case report.Economic evaluation of pegylated interferon plus ribavirin for treatment of chronic hepatitis C in Thailand: genotype 1 and 6.Response Guided Interferon Therapy for Genotype 3 of Chronic Hepatitis C: Compliance and Outcome.Roles of ITPA and IL28B genotypes in chronic hepatitis C patients treated with peginterferon plus ribavirin.Predictive factors for 24 weeks sustained virologic response (SVR24) and viral relapse in patients treated with simeprevir plus peginterferon and ribavirin Peginterferon Alfa-2a plus ribavirin in Japanese patients infected with hepatitis C virus genotype 2 who failed previous interferon therapy.

P2860

Q22305417-36B048EB-65E1-420F-907A-C24D8A2F9859 Q24628717-92D93D50-61FA-4053-9118-D2EF220ACA03 Q26745582-8E3C9447-C99F-40C0-B2B7-2320C8693ED4 Q26770020-76F31299-81D8-456C-9466-AC11DFC6042D Q26772324-A320AB6F-A861-41C1-831B-709AE0888AF4 Q26825715-B6C31EA8-9CC4-4507-A240-8C20B2D3461D Q26853138-08B49002-A5C9-46FA-B27E-D1D1E51E0315 Q28088762-AD0103A0-3110-4537-8F7F-44C124126482 Q28537754-77AC32E0-3793-4BC2-9B66-48DB485A03DD Q28553922-548D3062-DB3B-4ED0-9E4B-05F3F9A1D54C Q28608449-F83A9D31-BF95-4EC0-B011-6E094347A6CA Q30250088-7DFDED7D-B9EF-4D5B-A296-D80A536DA80D Q30417045-097DCD65-F2DF-4755-82F0-9C0D05491F69 Q31042796-2BD7FF1A-7F7C-4639-BE3C-87E36027D890 Q33407719-61C4C4B0-3039-4B4D-A8D7-913A9073BFD2 Q33559298-5AB2AB9C-1983-4B46-86C1-40D21AB9BA44 Q33734636-68BA33E2-CDCA-45A0-A2A0-B12E505F4BC5 Q33769085-AE6A988B-3169-47D5-8A66-8BDB47E1720A Q33845581-F32E5EC2-CA5E-47B8-A27E-9C32924BF5F2 Q33948241-5254F19C-1E22-43FA-ACF6-8A95B71E70C6 Q34003232-B6C76FD2-9FF4-4DAA-8E4A-254ABA423381 Q34411617-CB2FBFAE-914F-4A0E-A572-0DDC0214E4DB Q34634369-6B711092-AC6A-4634-BC8F-463883B6B758 Q34714220-0779B807-11E8-4B70-9AA6-B1AE4EC54845 Q34966853-86BDA45B-72BA-4299-A462-17750C579E54 Q35567832-9182CA25-3915-46C4-8D37-E311B092B2BC Q35602958-2A99BE87-0B34-4237-AB89-9769C78E8404 Q35609162-1D1DAB97-806F-4344-AAFA-C1E6E61D39B4 Q35835981-0D161379-7B06-4495-B4EB-08B509DE5597 Q35885715-858EA916-F57C-487B-8266-5CB3B785D6AA Q35895363-7A7D4765-142E-4FC8-80F6-87B5FDBFD05F Q35905985-BE3C4953-A4D9-45EB-A46D-5141FC40D844 Q35947900-840034EA-F8F8-4590-B2D6-F8F0BD1B6CB8 Q36009124-7F72A88C-6DC9-413B-8553-57F225046E89 Q36073283-65F27AFA-BC05-419D-BF0F-DF6419E78173 Q36095525-926B7F2C-FDBB-4486-BE7A-111FB0B711A6 Q36111011-6D0D8927-40B6-4ADF-92CB-51A18926F1DF Q36246785-BE2A5B87-1700-4F9D-A09C-69BAAA4B1EF6 Q36488315-B88B7528-F1EB-4C8B-B391-75BE5BE22592 Q36501509-28F62C81-177F-45BF-BBD5-55B20E65E957

P2860

APASL consensus statements and management algorithms for hepatitis C virus infection.

http://www.wikidata.org/entity/Q38552131

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

APASL consensus statements and management algorithms for hepatitis C virus infection.

@en

type

label

APASL consensus statements and management algorithms for hepatitis C virus infection.

@en

prefLabel

APASL consensus statements and management algorithms for hepatitis C virus infection.

@en

P1433

Q38552131-E452221D-4379-4B3A-8EC9-56EACD2C9D4F

P1476

Q38552131-39381B25-C561-4CF7-A39F-96088F16BA2A

P2093

Q38552131-1C47E040-D0DB-41D3-919B-2B099E769A44

Q38552131-4BF6D164-D9E8-4EE6-ACC7-9D2E6882525F

Q38552131-71A3DF8B-D89D-44D6-A39D-10DF319A4D57

Q38552131-88AA8E8E-0495-4257-BAA4-5BC6D8A903AF

Q38552131-8EA91605-CF90-413B-AAD4-2D00A4FED4B7

Q38552131-914C57E5-3525-4E3B-800A-4E61F37C35C5

Q38552131-977EF0B0-D169-47F8-B592-8E2C66A9D93F

Q38552131-AC982DD0-2DCB-4B45-AF29-FC403997CD69

Q38552131-CBF88E14-810C-446B-8D8C-C52F34FA04C2

Q38552131-CEC2A9BE-6C76-4C83-B8B1-1CE425B34CB4

P2860

Q38552131-022CF037-81C8-41F6-AC19-7D6AC72651E1

Q38552131-03166210-B262-4797-B090-9B6A5BD2B7A3

Q38552131-036A0FBE-7374-483E-9423-0FF96533F1B2

Q38552131-046A0425-E01D-4203-B612-9185089545FB

Q38552131-047B8D35-DB5D-445E-9180-78EA43B72632

Q38552131-0543B2D3-798C-4E21-B280-C3F7DCDB26AA

Q38552131-058F11B6-D94C-40A5-8E6C-B9B0BB93BE3E

Q38552131-0652AB26-2E98-48FC-B1F8-75D992743DAC

Q38552131-06E451E5-42AF-4DEC-BB14-AFA0D10524DF

Q38552131-08241723-9307-4686-BD29-96DCA75CE549

P2888

Q38552131-E7BED5E1-B710-409B-A051-704B294D7750

P304

Q38552131-91DFCB57-C3EF-4301-9512-37333E1C322E

P31

Q38552131-6203C1E3-05EE-4859-B30C-B4076399ABD8

P356

Q38552131-EF859412-A90B-43E7-8655-DC1DD2C35EF1

P433

Q38552131-B34E21D4-9A1D-4F76-8892-4F57F8A2CE7E

P478

Q38552131-F3B99496-C233-4565-8BD5-8AC091E5823A

P50

Q38552131-5290237A-6B1D-4466-A432-8981EE14AC37

Q38552131-6037AF36-CDA3-40C8-AA6B-7B53004BF9F7

P577

Q38552131-CA200EB0-3F91-48A2-97B1-31233AA841A6

P5875

Q38552131-C96EF17D-A012-4A49-8715-27920605A0CF

P6179

Q38552131-A13527A9-4B25-4FEB-BB15-76BECBBDD830

P698

Q38552131-FD9C4ED5-BFBC-47E2-AB6E-44B8509648B8

P356

S12072-012-9342-Y

P1433

Hepatology international

P1476

APASL consensus statements and management algorithms for hepatitis C virus infection

@en

P2093

Anuchit Chutaputti

http://www.w3.org/2001/XMLSchema#string

Geoffrey W McCaughan

http://www.w3.org/2001/XMLSchema#string

Jose Sollano

http://www.w3.org/2001/XMLSchema#string

Lai Wei

http://www.w3.org/2001/XMLSchema#string

Masao Omata

http://www.w3.org/2001/XMLSchema#string

Ming-Lung Yu

http://www.w3.org/2001/XMLSchema#string

Osamu Yokosuka

http://www.w3.org/2001/XMLSchema#string

Saeed S Hamid

http://www.w3.org/2001/XMLSchema#string

Seng-Gee Lim

http://www.w3.org/2001/XMLSchema#string

Shiv Kumar Sarin

http://www.w3.org/2001/XMLSchema#string

P2860

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

Boceprevir for previously treated chronic HCV genotype 1 infection

The natural history of hepatitis C virus (HCV) infection.

A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C

Correlates of spontaneous clearance of hepatitis C virus among people with hemophilia

A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C

Evaluation of Versant Hepatitis C Virus Genotype Assay (LiPA) 2.0

Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon

Improving the Diagnosis of Acute Hepatitis C Virus Infection with Expanded Viral Load Criteria

Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepatitis C

P2888

s12072-012-9342-y

P304

409-435

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12072-012-9342-Y

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Ryosuke Tateishi

P577

2012-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

257769349

http://www.w3.org/2001/XMLSchema#string

P6179

1038911223

http://www.w3.org/2001/XMLSchema#string

P698

26201405

http://www.w3.org/2001/XMLSchema#string